Shanghai, 5 November 2022 — Today, Bayer attends the China International Import Expo (“CIIE”) for the 5th consecutive year with its three business divisions: Pharmaceuticals (and Radiology), Consumer Health, and Crop Science.
Bayer’s booth at medical equipment and healthcare products exhibition area
Bayer, a global leader in life sciences, is generating buzz at the CIIE 2022 with a set of exhibitions themed “With 140-Year Presence in China, Bayer Advances a Better Life”. In accordance with its corporate vision of “Health for All, Hunger for None”, Bayer has increased the size of its booth in the expo's medical equipment and healthcare products exhibition area by 50% compared to last year, showcasing a wider variety of innovations, events, and interactive experiences that highlight its advantages in healthcare and agriculture. Meanwhile, in the crop and seeds subsection, Bayer's Crop Science Division has put up an installation to showcase its extensive germplasm pool and R&D capabilities, which are bolstering the prospects for value-added growth in China's seed industry in support of its high-quality, innovation-driven development.
Bayer’s booth in the crop and seeds subsection
“This year is the 5th time that Bayer participates in the China International Import Expo. This year is also the 140th anniversary of our company in China. Over these many years and decades, Bayer has witnessed China’s development and progress and we’ve been part of it proudly. At Bayer, we are committed to making people’s lives better and to advancing people’s health and nutrition. These are not only basic human needs; it is also what our company does best,” said Werner Baumann, Chairman of the Board of Management of Bayer AG. “Since Bayer’s first presence in the event 5 years ago, we’ve been working closely with our Chinese partners to introduce our latest research achievements through this national platform. As China’s most significant import exhibition, the CIIE very much facilitated international companies like Bayer, to share and grow together with China economic development. I wish the 2022 fair every success and I wish you have a wonderful stay at our Bayer Booth.”
New launches and debuts usher in an innovative era of life science
The CIIE is a globally renowned platform for China to further expand its high-level opening to the rest of the world, demonstrating China's resolve to actively open its market and enabling the rest of the world to benefit from the “China opportunity”. This high-level, open platform has become an essential venue for the presentation of new products and a must-attend event for showcasing cutting-edge innovations. Taking advantage of the new opportunities presented by the 5th CIIE, Bayer's four business segments are showcasing their innovations and technologies in various fields, dazzling the Chinese audience with an expanded portfolio of new releases and debuts, some of which have already been commercialized or are in the process of being commercialized at a fast-tracked pace thanks to the CIIE's ever-growing “spillover effect”.
Bayer’s Pharmaceuticals Division presents Verquvo®, a drug working differently to existing treatments, indicated for the treatment of patients with chronic heart failure, and Kerendia®, the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist, approved to treat adults with chronic kidney disease associated with type 2 diabetes. These two products, when shown at the 3rd and 4th CIIE as innovative products for the future, garnered widespread attention by virtue of their novel mechanisms of action. After being approved in China during the first half of this year, they are now on display at the 5th CIIE as available products. Their applications and approvals were processed at the same rate in China and other parts of the world, exemplifying the “window effect” and “spillover effect” of the CIIE, which has been a major catalyst in “turning exhibits into commodities”. Additionally, Bayer is proud to introduce Vitrakvi® (larotrectinib) as the first tumor-agnostic treatment exclusively designed for adults and children with TRK fusion cancer. Vitrakvi® represents a meaningful advancement in the fight against cancer, as it treats the oncogenic driver that causes tumor spread and growth, rather than where the tumor originates in the body. The approval of Vitrakvi® in China, offers a new precision treatment and opens a new era for patients harboring NTRK gene fusion.
For Radiology, Bayer is delighted to present two innovative and intelligent diagnostic imaging products and solutions for the first time in China, further proving its capabilities to empower precision treatment. They are: Calantic Platform, the novel platform integrated with artificial intelligence and medical imaging that is making its “China debut” at the CIIE, offering customers one-stop solutions; and the MEDRAD® Centargo CT power injection system, Bayer's flagship product of the high-efficiency CT power injection system that has three piston injection channels and provides informatics and intelligent modules.
Bayer’s Consumer Health Division pays tribute to the CIIE with the world premiere of Little Elevit, the infant product line of Elevit®. Two new products, Little Elevit vitamin D soft capsule and calcium and zinc vitamin D soft capsule, make their global debut at the booth. Designed to safeguard the first 1000 days of life, they help protect the bone health of Chinese babies. Same as Little Elevit, Redoxon® Calcium series originating from the CIIE and emerging from Bayer's collaboration with Sirio Pharma—Redoxon® triangle calcium for adults and sandwich calcium for children—are exhibited at the CIIE, launching a new calcium concept of bone health.
Bayer's Crop Science Division is debuting a vast array of products and solutions at the CIIE, including new crop protection solutions of Bayer Crop Efficiency, drone plus APP, digital agronomic platform and phenology mapping digital tool, digital breeding tool, Seminis home garden vegetable seeds and bi-color sweet corn Afficetion, DeKalb® six new corn varieties (by Bayer's joint venture), disruptive Short Stature Corn and Smart Corn System, Climate-Smart Business Models, etc. These items are designed to help advance agricultural modernization and strengthen food system resilience.
Expand local network and partnership to ride the waves in the vast blue sea opened up by China's high-quality development
As a “meeting point” where domestic and international circulation intersect, the CIIE opens up a world of opportunities for Bayer to embrace China's development opportunities and expand its local network and partnership in China, thereby strengthening its ties with all levels of government, industry partners, and consumers. With “win-win cooperation” as the guiding principle, Bayer is committed to expanding local collaboration to establish diversified R&D and business models and delivering more products and solutions to satisfy the needs of Chinese patients, consumers, and growers as quickly as feasible. Capitalizing on the momentum of the 5th CIIE, Bayer plans to launch a number of strategic partnerships in the coming days to fuel a new round of high-quality development for itself and China's healthcare and agriculture.
In the healthcare sector, Bayer actively responds to and supports the “Healthy China” initiative by bolstering local cooperation and constantly pursuing innovations that benefit Chinese patients and customers. During the CIIE, Bayer Consumer Health will enter into a series of cooperation agreements to integrate resources and share advantages with partners including the “Innovation China” initiative of the China Association for Science and Technology (CAST) supported by the experts group from the School of Public Health of Peking University, Jiangnan University, local innovative enterprise Xinhua Pharmaceutical, and Colori in order to meet the ever-increasing health needs of Chinese consumers. Bayer will also host a number of on-site events in collaboration with media outlets, governments, associations, experts, pharmacy chains, and upstream and downstream enterprises to raise patients' and consumers' knowledge and awareness of health management.
In the sphere of agriculture, Bayer's Crop Science Division has been joining forces with industrial chain partners across the whole life cycle of crop growth to advance China's agricultural and rural modernization. During the CIIE, it will sign an investment agreement with Qiantang District of Hangzhou city in order to better serve the Chinese and Asia-Pacific markets. It will also announce two new partners to join Bayer ForwardFarming network by signing a letter of intent with Shanghai Pudong and an agreement with Shandong Luwang for sustainable agriculture practice on row crop production in China. In the meanwhile, Crop Science plans to launch joint exhibitions and sign agreements with local partners including Yara, ICAN, Benlai.com, Luye Investment, Rivers Consulting to provide end-to-end digital agriculture solutions.
Carrying forward 140 years of legacy into a new era, Bayer's commitment to China remains unwavering
In the past 140 years, Bayer's dedication to being a pioneer in the life sciences in China and for China has never wavered. As China enters a new era of growth, Bayer continues to contribute to the implementation of Vision 2035 programs such as “Healthy China” and “Rural Revitalization”. Throughout its journey, Bayer has seen the search of a better life as its purpose and has spared no effort in supporting the Chinese people in achieving a healthier and more vibrant life.
In order to commemorate Bayer's 140 years of innovation in life sciences in China, Bayer has commissioned Zhou Liwei, a national intangible cultural heritage artist and the fourth-generation inheritor of the paper-cutting art of Wei County, to create a special artwork to honor the craft of paper-cutting, which has been passed down for over a century. Today at the CIIE, Bayer and Zhou jointed introduced the paper-cutting artwork, which had also been digitally reproduced by Bayer into a one-of-a-kind NFT. The digital artwork, which fuses time-honored traditional art with contemporary technology, celebrates a vision of a better life for the Chinese people that Bayer will continue to help shape over the next century.
Having already signed up for the 6th CIIE, Bayer, the global leader in life sciences, will continue to harness its global innovation network and leverage the event known to be the “Stage of China” that connects the entire world to continue to improve the lives of Chinese patients, customers, and growers by accelerating local innovation and providing China with more cutting-edge creative products and solutions.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.4 billion euros. For more information, go to www.bayer.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
